Literature DB >> 8002350

AIDS treatment costs during the last months of life: evidence from the ACSUS.

F J Hellinger1, J A Fleishman, D C Hsia.   

Abstract

OBJECTIVE: The volume and cost of services consumed by persons with AIDS (PWAs) during their last months of life are examined in this study. DATA SOURCES: This study utilizes data from the AIDS Costs and Service Utilization Survey (ACSUS). The ACSUS is the most comprehensive survey of medical services that are consumed by persons with HIV. STUDY
DESIGN: This study is restricted to persons with AIDS who survived the fifth time period (an approximately three-month period in the early spring and summer of 1992). The types and costs of services consumed during the fifth time period by PWAs who did survive (609) and who did not survive (79) the sixth time period are compared. DATA COLLECTION: The ACSUS consists of six interviews over an 18-month period from Spring 1991 to Fall 1992. PRINCIPAL
FINDINGS: Decedents were hospitalized more than four times as many days and experienced more than four times the number of home health visits as survivors. Both the average length of stay (19.3 days for decedents and 10.3 for survivors) and the frequency of hospitalization during the fifth time period (.70 for decedents and .28 for survivors) were higher for decedents than survivors. The levels of outpatient care (including emergency room care) and of prescription drug use were similar for decedents and survivors.
CONCLUSIONS: This study shows that the cost of treating decedents is more than three times the cost of treating survivors.

Entities:  

Mesh:

Year:  1994        PMID: 8002350      PMCID: PMC1070028     

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  11 in total

1.  HIV infection treatment costs under Medicaid in Michigan.

Authors:  D J Solomon; A J Hogan
Journal:  Public Health Rep       Date:  1992 Jul-Aug       Impact factor: 2.792

2.  Effects of the use of AZT on the medical care costs of persons with AIDS in the first 12 months.

Authors:  A A Scitovsky; M W Cline; D I Abrams
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

3.  Analysis of Michigan Medicaid costs to treat HIV infection.

Authors:  D J Solomon; A J Hogan; R R Bouknight; C T Solomon
Journal:  Public Health Rep       Date:  1989 Sep-Oct       Impact factor: 2.792

4.  Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991.

Authors:  A A Scitovsky; D P Rice
Journal:  Public Health Rep       Date:  1987 Jan-Feb       Impact factor: 2.792

5.  Medical care costs of patients with AIDS in San Francisco.

Authors:  A A Scitovsky; M Cline; P R Lee
Journal:  JAMA       Date:  1986-12-12       Impact factor: 56.272

6.  Trends in Medicare payments in the last year of life.

Authors:  J D Lubitz; G F Riley
Journal:  N Engl J Med       Date:  1993-04-15       Impact factor: 91.245

7.  Estimating the treatment costs of breast and lung cancer.

Authors:  M S Baker; L G Kessler; N Urban; R C Smucker
Journal:  Med Care       Date:  1991-01       Impact factor: 2.983

8.  The use and costs of Medicare services by cause of death.

Authors:  G Riley; J Lubitz; R Prihoda; E Rabey
Journal:  Inquiry       Date:  1987       Impact factor: 1.730

9.  New Jersey's Medicaid waiver for acquired immunodeficiency syndrome.

Authors:  C Merzel; S Crystal; U Sambamoorthi; D Karus; C Kurland
Journal:  Health Care Financ Rev       Date:  1992

10.  The use and costs of Medicare services in the last 2 years of life.

Authors:  J Lubitz; R Prihoda
Journal:  Health Care Financ Rev       Date:  1984
View more
  11 in total

Review 1.  Current controversies in the treatment of HIV infection and AIDS. An economic perspective.

Authors:  S Petrou
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

2.  National probability samples in studies of low-prevalence diseases. Part I: Perspectives and lessons from the HIV cost and services utilization study.

Authors:  M F Shapiro; M L Berk; S H Berry; C A Emmons; L A Athey; D C Hsia; A A Leibowitz; C A Maida; M Marcus; J F Perlman; C L Schur; M A Schuster; J W Senterfitt; S A Bozzette
Journal:  Health Serv Res       Date:  1999-12       Impact factor: 3.402

3.  Hospital care for persons with AIDS in European-Union countries; a cross-country comparison.

Authors:  M J Postma; H Kornarou; V Paparizos; R M Leidl; K Tolley; J Kyriopoulos; J C Jager
Journal:  Health Care Manag Sci       Date:  2000-01

Review 4.  Ganciclovir. A pharmacoeconomic review of its use as intravenous or oral maintenance therapy in the management of cytomegalovirus retinitis in patients with AIDS.

Authors:  C M Perry; R Davis
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

5.  The economic costs of caring for people with HIV infection and AIDS in England and Wales.

Authors:  S Petrou; M Dooley; L Whitaker; E Beck; E Kupek; J Wadsworth; D Miller; A Renton
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 6.  The cost of HIV treatment and care. A global review.

Authors:  E J Beck; A H Miners; K Tolley
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

7.  Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy.

Authors:  J J Caro; J A O'Brien; K Migliaccio-Walle; G Raggio
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

8.  Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid.

Authors:  J G Kahn; B Haile; J Kates; S Chang
Journal:  Am J Public Health       Date:  2001-09       Impact factor: 9.308

9.  Longitudinal patterns of medical service use and costs among people with AIDS.

Authors:  J A Fleishmann; V Mor; L L Laliberte
Journal:  Health Serv Res       Date:  1995-08       Impact factor: 3.402

10.  Primary care delivery is associated with greater physician experience and improved survival among persons with AIDS.

Authors:  Mari M Kitahata; Stephen E Van Rompaey; Peter W Dillingham; Thomas D Koepsell; Richard A Deyo; Wayne Dodge; Edward H Wagner
Journal:  J Gen Intern Med       Date:  2003-02       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.